Literature DB >> 20736855

Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study.

Hiroyuki Sakurai1, Hisao Asamura, Tomoyuki Goya, Kenji Eguchi, Yoichi Nakanishi, Noriyoshi Sawabata, Meinoshin Okumura, Etsuo Miyaoka, Yoshitaka Fujii.   

Abstract

INTRODUCTION: Women with non-small cell lung cancer (NSCLC) are more likely to have better survival than men. This study intended to assess gender differences in the survival of these patients in a large registry population.
METHODS: In 2005, the Japanese Joint Committee for Lung Cancer Registration performed a nationwide retrospective registry study regarding the prognosis and clinicopathologic profiles of patients who underwent resection for primary lung neoplasms in 1999. The registry data of 12,509 patients with NSCLC were analyzed in terms of gender differences in prognosis and clinicopathologic features.
RESULTS: There were 8353 (66.8%) men and 4156 (33.2%) women with a mean age at operation of 66.4 and 65.0 years, respectively (p < 0.001). Women had a higher incidence of adenocarcinoma (p < 0.001) and stage IA disease (p < 0.001) than men. The overall survival was significantly better in women than men. The 5-year survival rates (5-YSRs) for women and men were 75.6 and 57.9%, respectively (p = 0.0000). According to histology, the overall survival of women was significantly better than that of men for both adenocarcinoma (5-YSR, 77.7 versus 61.9%, p = 0.0000) and nonadenocarcinoma (5-YSR, 59.3 versus 53.1%, p = 0.035). In adenocarcinoma, women had a significantly better prognosis than men for pathologic stage I/II disease. However, in nonadenocarcinoma, there was no significant prognostic difference between the two genders in pathologic stage I/II disease.
CONCLUSIONS: Women with NSCLC, especially with an adenocarcinoma histology, had better survival than men. Women were more likely to have adenocarcinoma and stage IA disease, which might account for the better prognosis in women.

Entities:  

Mesh:

Year:  2010        PMID: 20736855     DOI: 10.1097/JTO.0b013e3181f1923b

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  37 in total

1.  The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients.

Authors:  Bing-Yen Wang; Jing-Yang Huang; Heng-Chung Chen; Ching-Hsiung Lin; Sheng-Hao Lin; Wei-Heng Hung; Ya-Fu Cheng
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-08       Impact factor: 4.553

2.  Surgery versus stereotactic body radiotherapy for clinical stage I non-small-cell lung cancer: propensity score-matching analysis including the ratio of ground glass nodules.

Authors:  N Tomita; K Okuda; S Osaga; A Miyakawa; R Nakanishi; Y Shibamoto
Journal:  Clin Transl Oncol       Date:  2020-07-23       Impact factor: 3.405

3.  Perioperative outcome of lung cancer surgery in women: results from a Spanish nationwide prospective cohort study.

Authors:  Juan J Fibla; Laureano Molins; Florencio Quero; José Miguel Izquierdo; David Sánchez; Jorge Hernández; Clara Bayarri; Marc Boada; Ángela Guirao; Antonio Cueto
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

Review 4.  Worldwide trend of increasing primary adenocarcinoma of the lung.

Authors:  Haruhiko Nakamura; Hisashi Saji
Journal:  Surg Today       Date:  2013-06-11       Impact factor: 2.549

5.  Survival Before and After Direct Surgical Quality Feedback in a Population-Based Lung Cancer Cohort.

Authors:  Matthew P Smeltzer; Nicholas R Faris; Meredith A Ray; Carrie Fehnel; Cheryl Houston-Harris; Philip Ojeabulu; Olawale Akinbobola; Yu-Sheng Lee; Meghan Meadows; R Samuel Signore; Lynn Wiggins; David Talton; Edmond Owen; Lawrence E Deese; Richard Eubanks; Bradley A Wolf; Paul Levy; E Todd Robbins; Raymond U Osarogiagbon
Journal:  Ann Thorac Surg       Date:  2018-12-27       Impact factor: 4.330

6.  Difference in Postsurgical Prognostic Factors between Lung Adenocarcinoma and Squamous Cell Carcinoma.

Authors:  Haruhiko Nakamura; Hiroki Sakai; Hiroyuki Kimura; Tomoyuki Miyazawa; Hideki Marushima; Hisashi Saji
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-10-02       Impact factor: 1.520

7.  Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status.

Authors:  Vei Mah; Mohammad Alavi; Diana C Márquez-Garbán; Erin L Maresh; Sara R Kim; Steve Horvath; Lora Bagryanova; Sara Huerta-Yepez; David Chia; Richard Pietras; Lee Goodglick
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

8.  Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer.

Authors:  D J Pinato; R J Shiner; M J Seckl; J Stebbing; R Sharma; F A Mauri
Journal:  Br J Cancer       Date:  2014-03-25       Impact factor: 7.640

9.  Risk factors of recurrence for resected T1aN0M0 invasive lung adenocarcinoma: a clinicopathologic study of 177 patients.

Authors:  Fan Yang; Kezhong Chen; Yida Liao; Xiao Li; Kunkun Sun; Dongmei Bao; Jun Wang
Journal:  World J Surg Oncol       Date:  2014-09-13       Impact factor: 2.754

10.  Quality of life after the initial treatments of non-small cell lung cancer: a persistent predictor for patients' survival.

Authors:  Irawati Lemonnier; Francis Guillemin; Patrick Arveux; Christelle Clément-Duchêne; Michel Velten; Marie-Christine Woronoff-Lemsi; Damien Jolly; Cédric Baumann
Journal:  Health Qual Life Outcomes       Date:  2014-05-15       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.